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Abstract
Metastatic cutaneous melanoma is highly resistant to cytotoxic drugs, and this contributes to poor prognosis.
In vivo studies on the chemosensitivity of metastatic melanoma are rare and hampered by poor response rates
to systemic chemotherapeutics. Patients who undergo isolated limb infusion (ILI) with cytotoxic drugs show high
response rates and are, therefore, a good cohort for studying chemosensitivity in vivo. We used tumors from
patients who underwent ILI to study the role of melanoma tumor-suppressor genes and oncogenes on mela-
noma chemosensitivity. Prospectively acquired tumors from 30 patients who subsequently underwent ILI with
melphalan and actinomycin-D for metastatic melanoma were investigated for mRNA expression levels of
p14ARF, p16INK4a, and MITFm. The mutation status of B-RAF, N-RAS, and PTEN were also determined. A high per-
centage of tumors had activating mutations in either B-RAF (15/30) or N-RAS (10/30) and only two tumors carried
altered PTEN. High expression of p16INK4a and absence of an activating B-RAF mutation independently predicted
response to treatment. Further, inducible expression of p16INK4a sensitized a melanoma cell line to death induced
by melphalan or actinomycin-D. This study shows that high expression of p16INK4a or the absence of activated
B-RAF correlates with in vivo response of melanoma to cytotoxic drugs.
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Introduction
Metastatic cutaneous melanoma has a poor prognosis with 2-year
survival of less than 30% in patients with visceral involvement [1].
This reflects the marked resistance of the disease to cytotoxic drugs.
Single-agent treatment with the alkylating agent dacarbazine (5-(3,3-
dimethyl-l-triazeno)-imidazole-4-carboxamide) remains the standard
best systemic therapy for metastatic melanoma [2]. Although overall
response rates to dacarbazine are less than 15% [3,4], certain patients
have highly sensitive tumors, and rare complete remissions are often
sustained [5]. To date, there are a few studies of in vivo molecular
determinants of chemosensitive melanomas, and the mechanisms in-
volved in melanoma chemoresistance have not yet been elucidated.
We sought molecular correlates of chemosensitivity in a unique
cohort of prospectively acquired tumor samples from patients with
metastatic melanoma receiving isolated limb infusion (ILI) chemo-
therapy [6]. Isolated limb infusion is a complex and technically de-
manding technique performed as a palliative procedure for extensive
inoperable locoregional recurrence in a limb, usually from multiple
in-transit seeding in cutaneous lymphatic vessels. A tourniquet is ap-
plied to isolate the circulation of the affected limb, allowing very high
doses of cytotoxic drugs to be administered locally, while minimizing
toxic systemic effects [6]. Isolated limb infusion is only performed
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in a few centers around the world on highly selected patients, and
although cohort size will always be limited, it provides a unique plat-
form for the study of chemosensitivity in melanoma. Firstly, unlike
most clinical situations, pretreatment fresh-frozen tumor samples are
readily available. Secondly, response rates to ILI are >50% [6], allow-
ing greater statistical power to assess molecular correlates of response
than in systemic chemotherapy, where response rates are <15% [7].
We selected for this analysis key candidate genes known to be
important in melanomagenesis and also linked to the regulation of
chemosensitivity [7]. We analyzed the expression of MITFm and
the p14ARF and p16INK4a melanoma tumor-suppressor genes and
the status of B-RAF, N-RAS, and PTEN.
The INK4a/ARF locus on chromosome 9p is the most frequently
deleted region in melanoma [8] and is inherited in mutated form
in 39% of melanoma-prone families [9]. INK4a/ARF encodes two
tumor-suppressor proteins, p14ARF and p16INK4a, both of which
have been shown to enhance the chemosensitivity of human cancer
cells [10–13]. p14ARF accumulates in response to oncogenic stimuli
and stabilizes p53, leading to cell cycle arrest or apoptosis (reviewed
in Sherr [14]). p16INK4a activates the retinoblastoma pathway by
inhibiting cyclin-dependent kinases 4 and 6 [15] leading to cell cycle
arrest and, in some instances, cell death [16].
The microphthalmia-associated transcription factor (MITF) regu-
lates development and differentiation of melanocytes [17] and is de-
regulated in melanoma. Increased levels of MITF may contribute to
melanoma progression as MITF induces expression of the antiapoptotic
molecule, Bcl-2 [18], and MITF ablation sensitizes melanoma cells
to cytotoxic drugs [19]. Microphthalmia-associated transcription
factor amplification is more frequent in metastatic melanoma and
correlates with decreased patient survival [19]. In normal melano-
cytes, MITF transcriptionally activates p16INK4a to promote cell cy-
cle arrest [20] and, as expected, MITF amplification is accompanied
by p16INK4a inactivation in melanoma cell lines [19].
Activating N-RAS and B-RAF mutations are the most common
oncogenic mutations in melanoma. Up to 80% of benign nevi [21]
and 25% to 66% of melanomas contain activating B-RAF mutations
[22,23]. Greater than 89% of these mutations alter a single amino
acid (V600E and V600K) and another 5% to 6% of melanoma-
associated B-RAF alterations affect exon 11 [24]. Activating N-RAS
mutations occur in 5% to 30% of melanomas [23,25,26], with the
highly recurrent mutations affecting Gly-12, Ala-18, and Gln-61,
accounting for approximately 12%, 5%, and 70% of melanoma-
associated mutations, respectively [24]. Activated B-RAF may also
co-operate with loss of the PTEN tumor-suppressor in promoting
melanoma development. PTEN attenuates phosphoinositide 3-kinase
(PI(3)K/AKT) signaling, and the simultaneous activation of B-RAF
and loss of PTEN simulate N-RAS activation to promote melanoma
development [27,28]. The high frequency of N-RAS and B-RAF
mutations in melanoma and the fact that these mutations have been
correlated with poor prognosis [23] indicate that they are potential
therapeutic targets, and yet there have been few studies investigat-
ing N-RAS/B-RAF status and melanoma response to common chemo-
therapeutic agents.
Materials and Methods
Patients
Fresh-frozen tumor excision biopsies were obtained from 30 con-
secutive consenting patients undergoing elective therapeutic ILI
at the Sydney Melanoma Unit. These patients had not undergone
prior systemic therapies. Catheters were inserted percutaneously
into the axial artery and vein of the affected limb, and a pneumatic
tourniquet was inflated proximally. Melphalan (7.5-mg/L tissue) and
actinomycin-D (75-μg/L tissue) were rapidly infused into the arte-
rial catheter while the limb was isolated. The infusate was then cir-
culated for 20 to 30 minutes by catheter using a syringe attached
to a three-way tap. Finally, the limb was flushed with saline before
the tourniquet was released and the catheters were removed [6].
Patient details are shown in Table 1. All had lower limb skin me-
tastases and were eligible for the study if at least one lesion greater
than 10 mm3 in volume could be excised, leaving at least one other
lesion in the same field that could be evaluated for response. Re-
sponse was determined by standard response evaluation criteria in
solid tumors at 4-week intervals until disease progression, recorded by
digital photography, and confirmed by independent review of these re-
cords. The study was approved by the Sydney South West Area Health
Service, Protocol No. X00-0274 and was initiated in March 2001.
RNA Extraction and cDNA Synthesis
The excised lesion was frozen immediately in liquid nitrogen.
Samples were trimmed of surrounding tissue, and RNA was extracted
using Trizol (Sigma, St. Louis, MO) and purified using RNeasy col-
umns (Qiagen, Valencia, CA). Samples with evidence of melanin
were cleaned by heating to 65°C for 5 minutes during Trizol extrac-
tion or by using Bio-Spin P-30 Tris columns (Bio-Rad, Hercules, CA).
cDNAwas synthesized from 100 ng to 1 μg of RNA using Superscript
III (Invitrogen, Carlsbad, CA) with oligo-dT primers. No-SuperScript
III enzyme controls were performed to ensure there was no contami-
nating genomic DNA.
Real-time Reverse Transcription–Polymerase Chain Reaction
Real-time reverse transcription–polymerase chain reaction (RT-PCR)
was performed using a Corbett Rotorgene 3000 with Platinum SYBR
Green qPCR Master Mix (Invitrogen) for MITF. For the remaining
genes, TaqMan probes were used; the master mix used for p16INK4a,
18S, and hP0 was Platinum qPCR SuperMix-UDG (Invitrogen); and
Brilliant qPCR Master Mix (Stratagene, La Jolla, CA) was used for
p14ARF. DMSO 3% was added to p16INK4a and p14ARF reactions,
and Mg2+ increased to 5 mM in p14ARF reactions. Primers used were
as follows:
MITFm_fwd: CCG TCT CTC ACT GGA TTG GTG
MITFm_rev: GCT TGC TGT ATG TGG TAC TTG G
p16INK4a_fwd: GCC CAA CGC ACC GAA TAG
Table 1. Details of Patients Treated by ILI with Melphalan and Actinomycin-D.
Responders Nonresponders
Male/Female 5:16 2:7
Age, median (range), years 75 (48-93) 78 (46-86)
Best response, n CR, 5 SD,* 7
PR, 16 PD, 2
Mean time to best response 57 days N/A
Mean time to PD in ILI field 272 days in responders
(from 3 CR and 10 PR;
674 days in CR,
152 days in PR)
94 days in nonresponders
(from 2 PD and 5 SD;
118 days in SD,
49 days in PD)
CR indicates complete response; NA, not applicable; PD, progressive disease; PR, partial response;
SD, stable disease.
*Mean duration of stable disease was 74 days (derived from 5 SD).
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p16INK4a_rev: ACG GGT CGG GTG AGA GTG
p16INK4a_probe: FAM6-TCA TGA TGA TGG GCA GCG
CC-TAMRA (A/B 450025)
p14ARF_fwd: CTA CTG AGG AGC CAG CGT CT
p14ARF_rev: ACG GGT CGG GTG AGA GTG
p14ARF_probe: FAM6-TCA TGA TGA TGG GCA GCG
CC-TAMRA (A/B 450025)
Equal loading was ensured by adjusting samples to the same aver-
age expression levels for the ribosomal proteins human P0/36B4 and
18S. hP0 and 18S levels were measured by real-time RT-PCR using
VIC-labeled predeveloped assay reagent probes (Applied Biosystems,
Foster City, CA).
Mutation Status
Mutation status of N-RAS at codons 12, 16, 18, and 61 was de-
termined by RT-PCR cleaned up with ExoSapIT (USB Corporation,
Cleveland, OH) and sequenced on an ABI PRISM 3100 (Applied
Biosystems). Primers used were as follows: N-RAS61_fwd: CTG
ACA ATC CAG CTA ATC, N-RAS61_rev: GTC TTT TAC TCG
CTT AAT CTG, N-RASex1_fwd: AGC TTG AGG TTC TTG
CTG GTand N-RASex1_rev: CTC TCA TGG CAC TGTACT CT.
Mutation status of B-RAF at codon 600 was determined by single-
strand conformation polymorphism analysis. A 228-bp fragment of
B-RAF spanning codon 600 was amplified by RT-PCR (forward
primer: ATA GAT ATT GCA CGA CAG AC; reverse primer:
ATC TTG CAT TCT GAT GAC TTC), placed in formamide/
EDTA loading buffer, and denatured at 95°C for 10 minutes then
placed on ice for 2 minutes. Samples were run on an SSCP gel
(10% polyacrylamide gel containing 1× Tris-glycine buffer and 5%
glycerol) for 3.5 hours at 22°C and then the gel was silver-stained.
Samples showing aberrant bands on the gel were sequenced to con-
firm the mutation.
Mutation status of BRAF exon 11 and part of exon 12 was deter-
mined by sequencing RT-PCR products as detailed above. BRAF
exon 11/12 primers were as follows: BRAFexon11/12_fwd: GAC
GGG ACT CGA GTG ATG AT, BRAFexon11/12_rev: CTG CTG
AGG TGT AGG TGC TG.
Mutation status of PTEN cDNA was determined by sequencing
RT-PCR products as described in the study of Liu and Kagan
[29]. Partial PTEN sequences were obtained for tumor samples
006 and 026 owing to limited RNA.
All sequences were analyzed by visual inspection and using the
Australian National Genomic Information Service BioManager.1
Statistical Analysis
The data were analyzed using SPSS for Windows 15.0. Two-tailed
tests with a significance level of 5% were used throughout. p16INK4a,
p14ARF, and MITFm expression levels were log-transformed to ap-
proximate normality before analysis. Response was considered as a
dichotomous outcome, with patients showing complete or partial re-
sponse classified as responding and patients with stable disease or
progressive disease classified as not responding. Logistic regression
analysis was used to test for the association between all variables
and the presence of response. The odds ratios (ORs) and their
95% confidence intervals (CIs) were used to quantify the degree of
association between the independent predictors of response identified
using multiple logistic regression with backward stepwise variable
selection. Mann-Whitney correlation was used to quantify the de-
gree of association between B-RAF and the expression of p16INK4a,
p14ARF, and MITFm.
Cell Culture
The WMM1175_p16INK4a cell clone carries the stably integrated-
p16INK4a gene under isopropyl-β-D-1 thiogalacto pyranoside–inducible
expression control and has been described previously [30]. Melanoma
cells were grown in DMEM/10% FBS in a 37°C incubator with
5% CO2.
In cytotoxicity assays, cells were exposed to 1-mM IPTG for
4 days, followed by the addition of medium containing IPTG
and drugs to a final concentration of 25-nM actinomycin-D or
200-μM Melphalan for a further 24 hours.
Cell Cycle and Apoptosis Analysis
For cell cycle analysis, cells were fixed in 70% ethanol at 4°C for
at least 1 hour, washed in PBS, and stained with propidium iodide
(50 μg/mL) containing ribonuclease A (50 μg/mL). DNA content
from at least 2000 cells was analyzed using ModFIT software (Verify
Software House, Topsham, ME). Numbers of cells with sub-G1 con-
tent were determined using CellQuest software (Becton Dickinson,
Franklin Lakes, NJ). Annexin V staining was performed as detailed
by the manufacturer (Sigma). Western blots were probed for p16INK4a
(sc-467; Santa Cruz Biotechnology, Santa Cruz, CA) and β-actin
(AC-74; Sigma).
Results
Patient Response
Fresh-frozen tumor biopsy samples from 30 melanoma patients
who subsequently underwent ILI were analyzed. Tumor response
to ILI was classified as responsive, which included tumors showing
complete response (n = 5) and partial response (n = 16), and non-
responsive, which incorporated stable disease (n = 7) and disease that
progressed (n = 2; Table 1).
N-RAS and B-RAF Are Frequently Mutated in Melanoma
Most N-RAS and B-RAF mutations in melanoma occur at codons
61 (Q61K and Q61R) and 600 (V600E and V600K), respectively
[23,31]. In addition, a small proportion of melanomas carries altera-
tions affecting exon 11 of B-RAF and N-RAS at Gly-12 and Ala-18
[24]. We analyzed tumor samples for mutations affecting these
codons using SSCP (Figure 1) and sequencing (Figure 2). Of the
30 tumors, 10 (33%) showed mutation in N-RAS and only codon
61 was altered. Another 15 (50%) melanomas contained B-RAF al-
terations; 9 with V600E, 4 with V600K, 1 with G466V, and 1 with
L485F (Table 2). As expected, activation of N-RAS and B-RAF in our
panel of melanoma tumors was mutually exclusive, and all mutations
were heterozygous (Figure 2).
Expression Analysis of p16INK4a, p14ARF, and MITF
There was considerable variation in p14ARF and p16INK4a transcript
expression (Figure 3). Most tumors (approximately 60%) displayed
very low expression of both p14ARF and p16INK4a. In most cases, the
expression of these transcripts was comparable, which is expected con-
sidering that these genes share genomic sequence. Tumors 004, 005,1www.angis.org.au.
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Figure 2. Sequence analyses of amplified B-RAF and N-RAS transcripts. The nucleotide and codon changes encoded are shown on
the left of each sequence. Numbering is based on GenBank accession NM_004333 (B-RAF) and NM_002524 (N-RAS). wt indicates wild
type sequence.
Figure 1. SSCP analysis of a B-RAF RT-PCR fragment encompassing codon 600. Wild type (wt) control B-RAF PCR product was gen-
erated from the WMM1215 melanoma cell line and the B-RAFV600E mutant control was amplified from a B-RAFV600E expression plasmid.
Amplified B-RAF cDNA from tumor samples are also shown with V600E and V600K mutation–positive tumors marked E and K, respec-
tively. The remaining unmarked tumor samples were wild type at codon 600.
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007, 012, 030, and 041 showed discordant levels of the p16INK4a and
p14ARF transcripts. The expression ofMITF was also variable with only
four tumors (006, 008, 025, and 045), displaying very low levels of this
transcript (Figure 3).
Absence of B-RAF Mutation and p16INK4a Expression
Correlate with Better Response
We investigated whether the presence of N-RAS or B-RAF mutation
or the expression level of p16INK4a, p14ARF, orMITF predicted response
to chemotherapeutic drugs. The independent predictors of response in
this tumor set were the absence of a B-RAF mutation and high log-
transformed p16INK4a expression (Table 3). N-RAS mutation was also
Table 2. B-RAF and N-RAS Mutation Status of 30 Melanomas.
Mutation Nucleotide n Tumors Samples
N-RASQ61R A435G 8 004, 010, 011, 018, 019,
042, 044, 046
N-RASQ61K C434A 1 030
N-RASQ61K AC433-434TA 1 001
B-RAFV600E T1860A 9 002, 003, 007, 008, 015,
022, 023, 038, 041
B-RAFV600K GT1859-60AA 4 005, 025, 027, 043
B-RAFG466V G1458T 1 012
B-RAFL485F G1516T 1 028
No mutation 5 006, 021, 026, 032, 045
Total 30
Figure 3. Relative expression levels of p14ARF, p16INK4a, and MITFm in melanoma tumors was determined using quantitative real-time
RT-PCR. The mutation status of B-RAF and N-RAS for each tumor is also shown (N = mutant N-RAS, B = mutant B-RAF, - = wild type
N-RAS and B-RAF). Tumor response classification is also indicated. CR indicates complete response; PD, progressive disease; PR,
partial response; SD, stable disease.
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weakly associated with response; although on multivariate analysis,
B-RAF was the more powerful predictor, with seven of nine nonrespon-
sive tumors harboring an activated B-RAF mutant. The expression
levels of p14ARF and MITF did not correlate with response. Further,
a Mann-Whitney test showed that there was no correlation between
the presence of B-RAF mutation and p16INK4a, p14ARF, or MITF ex-
pression (P = .861, P = .423, and P = .922, respectively).
Mutations Affecting the PTEN Tumor-Suppressor Are Not
Common in Melanoma
Considering that oncogenic mutations affecting N-RAS and B-RAF
were not equivalent in predicting melanoma response, it seemed
likely that the MAP kinase–signaling cascade, which is activated by
both N-RAS and B-RAF, may not significantly influence treatment
response. The main signaling cascade differentially activated by
N-RAS and B-RAF is the PI(3)K/AKT pathway, and the integrity of
this pathway was analyzed by screening the PTEN tumor-suppressor,
which attenuates PI3K signaling. As expected, PTEN mutations were
not common in our panel of melanomas and were identified in only
three tumors (003, 005, and 045). The 045 tumor, which was wild
type for both N-RAS and B-RAF, expressed wild type PTEN and
PTEN with the G44G silent amino acid change (data not shown).
Tumor 003 expressed BRAFV600E and carried the homozygous PTEN
mutant I253N, and tumor 005 expressed oncogenic B-RAFV600K and
was heterozygous for the PTEN P213S alteration (Figure 4).
p16INK4a Expression Induces Melanoma Cell Death
To investigate the impact of p16INK4a expression on melanoma cell
survival, we used a stable p16INK4a-inducible melanoma line. Expres-
sion of p16INK4a in this WMM1175_p16INK4a cell clone was in-
duced with 1-mM IPTG for a 5-day period (Figure 5A). As shown
in Figure 5B, induction of p16INK4a led to potent G1 cell cycle arrest
and cell death, as determined by the increased sub-G1 population.
Accumulation of p16INK4a also sensitized WMM1175_p16INK4a
cells to death in response to the cytotoxic drugs melphalan and
actinomycin-D. In particular, the sub-G1 population increased from
18% in the presence of p16INK4a alone to 26% with the addition of
actinomycin-D and 30% in the presence of p16INK4a and melphalan
(Figure 5B). Consistent with these data, a significantly higher percent-
age of Annexin V–positive apoptotic cells was also observed in re-
sponse to actinomycin-D or melphalan when p16INK4a was induced
(Figure 5C ).
Discussion
In this study, we investigated the in vivo response of melanoma me-
tastases to cytotoxic drugs administered by ILI to determine whether
response correlated with the expression of p16INK4a, p14ARF, and
MITFm and the mutation status of N-RAS, B-RAF, and PTEN. We
have shown that high p16INK4a expression and the absence of mutant
active B-RAF correlate with chemotherapeutic response of melanoma
tumors. The fact that melanomas commonly lack p16INK4a and carry
active B-RAF may therefore contribute to chemoresistance.
The high prevalence of B-RAF and N-RASmutations (25/30) found
in our melanoma samples is similar to other studies [22,23,26]. Like-
wise, the Gln-61 and Val-600 codons of N-RAS and B-RAF, re-
spectively, were the common targets of alteration in our melanoma
tumors (Table 2). In addition, one tumor contained the B-RAF
G466V mutation and another, the L485F B-RAF mutant. The
G466V mutation has been identified in melanoma and lung cancer
[22,32,33], whereas the L485F mutation has not been reported
in melanomas previously [22,24] but has been identified in individ-
uals with the sporadic developmental disorder cardiofaciocutaneous
Table 3. Best-Fitting Multiple Logistic Regression Model of Response Together with Adjusted ORs
and Their 95% CIs for Independent Predictors of Response.
B SE P OR 95% CI for OR
Lower Upper
BRAF mutation −2.44 1.18 .039 0.087 0.009 0.88
log p16INK4a 0.60 0.26 .022 1.83 1.1 3.06
Constant −0.882 1.27 .49 0.41
Figure 4. Sequence analyses of amplified PTEN transcripts derived from tumor samples 003 and 005. The nucleotide and codon changes
encoded are shown on the left of each sequence. Numbering is based on accession NM_000314. wt indicates wild type sequence.
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syndrome [34,35]. More importantly, like the V600 B-RAF muta-
tions, both G466V and L485F are within the B-RAF kinase domain
and have elevated kinase activity in vivo [34–37]. N-RAS and B-RAF
mutations were mutually exclusive, as previously reported [22], pre-
sumably because both these gene products signal through the MAP
kinase pathway.
The differential role of B-RAF and N-RAS in predicting melanoma
chemosensitivity (this study) and survival [38] may involve the
PI(3)K/AKT pathway. Unlike B-RAF, N-RAS activates the PI(3)K/
AKT pathway and several studies have implicated activation of the
PI(3)K pathway as another crucial event in the progression of mela-
noma [39]. In particular, RAS activation of the PI(3)K/AKT pathway
controls the activation of endoplasmic reticulum stress (ER-stress) re-
sponse [39], which can activate cytoprotective or cytotoxic effects
depending on the cellular environment [40]. When ER-stress is
persistent or excessive, it can trigger cell death. For instance, the
ER-stress–inducer thapsigargin selectively enhanced tumor necrosis–
related apoptosis–inducing ligand (TRAIL)–induced apoptosis in
melanoma cells [41]. B-RAF and RAS also differ in their capacity to
promote growth arrest in normal human cells [42] and in their ability
to produce invasive melanocytic neoplasia [27]. Finally, microarray
studies show melanomas with an activating N-RASmutation have dif-
ferent gene expression patterns to those with activating B-RAF muta-
tions [43], and tumors containing N-RASQ61R are less dependent on
MEK than tumors with BRAFV600E [44].
The combined activation of B-RAF and loss of PTEN may simu-
late oncogenic N-RAS activity to simultaneously activate the MAP
kinase and PI(3)K pathways. Accordingly, melanomas rarely express
oncogenic N-RAS and altered PTEN [45], whereas they frequently
carry oncogenic B-RAF and mutated PTEN [27]. In our sample set,
only two melanomas carried missense PTEN mutations. These muta-
tions (P213S and I253N) presumably inactivate PTEN because they
are located in the PTEN lipid-binding domain and have been iden-
tified in a human glioma and endometrial cancer [46,47]. The two
tumors with PTEN loss also expressed oncogenic forms of B-RAF,
but patient response did not relate to PTEN status; 005 showed com-
plete response, whereas 003 had stable disease after therapy. Consid-
ering the low frequency of PTEN alterations detected in melanomas,
a significantly larger set of melanoma tumor samples needs to be
Figure 5. Induced expression of p16INK4a promotes arrest and sen-
sitizes cells to cell death. (A) WMM1175_p16INK4a melanoma cells
were induced to express p16INK4a with the addition of 1-mM IPTG
to the medium for 4 days, then treated with IPTG and actinomycin-
D, melphalan or carrier control for 24 hours. Accumulation of
p16INK4a was determined by Western blot analysis, and detection
of β-actin was used to demonstrate equal protein loading. (B) The
cell cycle distribution of the WMM1175_p16INK4a cells was exam-
ined using propidium iodide (PI) staining. Cells were left untreated
(left panels) or incubated with medium containing 1-mM IPTG for
4 days (right panels). Induced and uninduced cells were then treated
with ethanol (Control), 25-nM actinomycin-D (ActD), or 200-μM
melphalan (Mel) with or without IPTG for a further 24 hours. (C)
Apoptosis assays of the WMM1175_p16INK4a cells, monitored by
Annexin V–FITC staining. Cells were left untreated (−IPTG) or incu-
bated with medium containing 1-mM IPTG for 4 days (+IPTG). In-
duced and uninduced cells were then treated with ethanol
(Control), 25-nM actinomycin-D (ActD), or 200-μM melphalan
(Mel) with or without IPTG for a further 24 hours. Error bars repre-
sent SD from at least two independent experiments.
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analyzed to accurately define the contribution of PTEN and the PI(3)
K pathway to melanoma chemosensitivity. This is particularly impor-
tant because the combination of B-RAF inhibitors with PI(3)K inhibi-
tors have been shown to co-operate in preventing melanoma cell
proliferation and consistently enhanced melanoma chemosensitivity
and suppressed invasive tumor growth [48].
Our set of melanoma tumor samples displayed heterogeneity
in MITF expression with no apparent correlation with chemo-
sensitivity. Inhibition of MITF function in melanoma may trigger
CDK2-mediated growth arrest [49] or apoptosis through Bcl-2
down-regulation [18]. Accordingly, MITF loss has been shown
to sensitize melanoma cells to the cytotoxic agents, cisplatin and
docetaxel [19]. Alternatively, increased MITF expression has been
shown to induce cell cycle arrest by activating the expression of
the CDK inhibitor p16INK4a [20]. Interestingly, MITF-M expression
may be down-regulated during the spontaneous regression of mela-
noma [50]. We observed no association between MITF and p16INK4a
expression in our melanoma tumors (data not shown).
MITF activity is also regulated by the MAP kinase pathway; acti-
vation of MAP kinase signaling phosphorylates MITF, which simul-
taneously increases its transactivation potential and targets it for
degradation through the 26S proteasome [51,52]. Thus, MITF am-
plification, which is found in 20% to 30% of melanomas, is often
accompanied by B-RAF mutation and p16INK4a loss [19]. However,
we did not see any correlation between MITF and B-RAF expression
levels in this study (data not shown).
Ectopic expression of p14ARF enhances chemosensitivity in human
tumor cell lines [10] and p14ARF expression has been associated with
improved prognosis in several cancers, including acute myeloid leu-
kemias [53,54]. However, no association between p14ARF expression
and response was seen in our panel of melanoma tumors. Further,
in a recent microarray study of melanoma tumors, p14ARF expression
was not associated with survival [55]. Although p14ARF is frequently
lost in human melanomas, this usually occurs in combination with
p16INK4a loss. Moreover, most mutations affecting the INK4a/ARF
locus target p16INK4a for inactivation [56], indicating that, in hu-
mans, p16INK4a is the critical INK4a/ARF tumor-suppressor.
p16INK4a loss correlates with poor prognosis in human cancers
such as melanoma, leukemia, and renal cancers [57,58]. Although
there is no necessary biological connection between poor prognosis
and chemoresistance, it is possible that the high frequency of loss of
p16INK4a in melanoma is a direct contributor to treatment failure.
Consistent with this hypothesis, we found that retention of p16INK4a
was associated with melanoma chemosensitivity and that accumula-
tion of p16INK4a promoted the death of melanoma cells. More im-
portantly, p16INK4a co-operated with the cytotoxic drugs melphalan
and actinomycin-D to enhance melanoma cell death. The mecha-
nism by which p16INK4a expression promotes cell death in response
to drugs requires investigation. This is especially relevant because
melanoma cells have usually lost p16INK4a and display an intrinsic
resistance to drug-induced cell death.
Although most tumor samples displayed comparable levels of
p14ARF and p16INK4a message, only p16INK4a expression predicted dis-
ease response. This is because two nonresponders (012 and 041) ac-
cumulated high levels of p14ARF mRNA but no p16INK4a transcript
(Figure 3). The intimate genomic organization of the p16INK4a and
p14ARF genes allows for co-ordinated expression [59], although in-
dependent promoters primarily drive their expression [60]. We have
previously shown that disruption of this co-ordinate expression is
associated with melanoma predisposition [59], but in this report, we
found no evidence that discordant expression of p16INK4a and p14ARF
correlated with treatment response.
In summary, this study shows that p16INK4a expression and absence
of activating B-RAF mutation correlate with in vivo response of meta-
static melanoma exposed to high doses of locally administered cyto-
toxic drugs. This study reinforces the importance of the INK4a/ARF
locus and highlights the PI(3)k/AKT pathway, in the regulation and
execution of apoptosis in melanoma, and suggests directions to im-
prove its responsiveness to conventional chemotherapeutic agents.
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